The intricate interplay between the host and its microbiome in metastatic disease is a formidable challenge to identify novel early-detection biomarkers and prognostic prediction. Creative Biolabs' metagenomics-based metastatic tumor microbiome analysis service aims to address this scientific frontier. Leveraging advanced metagenomic sequencing, we furnish a comprehensive analysis of the microbial landscape associated with metastatic tumors, thereby illuminating its functional impact and revealing previously uncharacterized microbial signatures, which is useful for accelerating the pipeline for novel drug discovery and the development of sophisticated diagnostic tools.
The microbiome has emerged as a potent and increasingly validated determinant in oncology, modulating tumor progression, therapeutic response, and clinical outcomes. Emerging evidence demonstrates that tumors can induce gut dysbiosis, thereby establishing a feed-forward loop that accelerates tumor progression. Furthermore, the microbial landscape can act as a predictive biomarker for metastasis and a key modulator of the immune response to therapies. The identification of distinct microbial signatures in early-stage malignancies indicates the importance of the development of minimally invasive diagnostics. Our service provides high-resolution data and interpretive depth, which is vital to elucidate and clinically exploit these host-microbiome interactions.
Fig.1 The application of metagenomics.1
Creative Biolabs' metagenomics based metastatic tumor microbiome analysis service offers a comprehensive, rigorously validated pipeline for dissecting the intricate crosstalk between microbial communities and oncogenesis. By coupling state-of-the-art sequencing workflows with refined bioinformatic toolkits, we deliver high-resolution snapshots of taxonomic composition, functional capacity, and metabolic signatures present within metastatic lesions. These data allow investigators to pinpoint microbial biomarkers that correlate—sometimes subtly, sometimes robustly—with disease trajectory, metastatic propensity, and therapeutic responsiveness. All deliverables derive from peer-reviewed protocols, ensuring clarity and reliability without unnecessary jargon.
We offer a comprehensive suite of sequencing strategies tailored to your research objectives:
We have state-of-the-art analytical pipelines:
We offer a seamless, end-to-end service pipeline that encompasses every step from sample preparation to final report delivery.
We possess the following competitive advantages.
A1: We can analyze various samples including fresh-frozen or FFPE metastatic biopsies, matched primary tumors, and stool samples. For project-specific guidance, our scientific team is available to tailor collection and processing protocols to your exact requirements. We encourage you to contact us to discuss the specific requirements for your project.
A2: Compared with 16S sequencing provides a taxonomic profiling, our metagenomics approach interrogates the entire genomic content of the sample, enabling species-level resolution and direct analysis of functional genes, which will give you a more complete picture of the role of microbiome.
A3: You will receive a comprehensive data package including raw and processed sequencing files, in-depth taxonomic and functional-pathway reports, and an executive summary integrating microbial signatures with your clinical metadata. All results are presented with full methodological transparency to facilitate immediate and reliable decision-making.
Creative Biolabs combines deep analysis with sophisticated machine learning techniques and provides a comprehensive metagenomic profile, which are critical for understanding both disease progression and therapeutic response. Furthermore, our pan-cancer approach, supported by a wealth of published data, demonstrates our capability to profile a wide spectrum of metastatic tumors. Therefore, we provide a powerful tool for the discovery of biomarkers and the development of new therapies.
"Creative Biolabs' Metagenomics Based Metastatic Tumor Microbiome Analysis Service has significantly improved our ability to identify novel microbial biomarkers for early-stage colorectal cancer detection. The detailed functional analysis helped us uncover metabolic pathways associated with the disease, far beyond what we could achieve with standard methods." —Dr. K***en
"The high-quality data from Creative Biolabs was pivotal to the success of our immunotherapy project. The integrated analysis uncovered the link between the patient microbiome and treatment efficacy, specifically with anti-PD-1 therapy, providing a translational inflection point for the program. Moreover, the clear and comprehensive reporting made it easy for our team to integrate the findings into our clinical strategy." —E. H***an
"Leveraging the platform of Creative Biolabs, we conducted a comprehensive pan-cancer investigation, revealing a surprising connection between the anatomical site of the tumor and its resident microbial community. This insight is completely reshaping our understanding of cancer etiology and catalyzing a strategic overhaul of our drug-development pipeline." —Dr. T. P***o
Contact us for more information and to discuss your project.
Reference